Abstract
Recently, microarray technology is reshaping the molecular biology, given the high number of fields of application like, gene expression analysis, rapid sequencing of DNA, mapping of allelic variation, identification polymorphisms. It is a recently developed technique, which allows analysing thousands of genes in a very short time. Due to the powerful nature of this genetic approach, the number of researches using microarray technology boosted in the last years (less than ten papers from 1995 to 1997, up to approximately one thousand in the following 5 years -PubMed). Nevertheless, in spite of the promising fields of application, many drawbacks need to be carefully considered before generalizing the results obtained with this new technology. In fact, up to now a number of drawbacks have been described in the use of DNA microarray: many errors of incorporation during the manufacturing of the chips, loss of splicing variants, variable reliability of differential expression data, low specificity of cDNA microarray probes, discrepancy in fold change calculation for a given gene and so on. In spite of all those troubles, there is no doubt that this new promising technology could give an overall idea of gene organization and expression and might contribute to understanding the molecular mechanisms involved in processes as disease diagnosis or drug discovery (Pharmacogenetics and Pharmacogenomics). The goal of the present review is to suggest a targeted use of DNA chip technology in the field of pharmacogenetics (with the example of antidepressants), suggesting the inclusion of only those genes, possibly candidates, through a step by step analysis of the pathways involved in the pharmacological action of antidepressants.
Keywords: pharmacogenetics, microarray, chips, review
Current Genomics
Title: The Use of DNA Microarray in the Pharmacogenetics of Antidepressants: Guidelines for a Targeted Approach
Volume: 5 Issue: 6
Author(s): Cristina Lorenzi, Viviana Tubazio, Alessandro Serretti and Diana De Ronchi
Affiliation:
Keywords: pharmacogenetics, microarray, chips, review
Abstract: Recently, microarray technology is reshaping the molecular biology, given the high number of fields of application like, gene expression analysis, rapid sequencing of DNA, mapping of allelic variation, identification polymorphisms. It is a recently developed technique, which allows analysing thousands of genes in a very short time. Due to the powerful nature of this genetic approach, the number of researches using microarray technology boosted in the last years (less than ten papers from 1995 to 1997, up to approximately one thousand in the following 5 years -PubMed). Nevertheless, in spite of the promising fields of application, many drawbacks need to be carefully considered before generalizing the results obtained with this new technology. In fact, up to now a number of drawbacks have been described in the use of DNA microarray: many errors of incorporation during the manufacturing of the chips, loss of splicing variants, variable reliability of differential expression data, low specificity of cDNA microarray probes, discrepancy in fold change calculation for a given gene and so on. In spite of all those troubles, there is no doubt that this new promising technology could give an overall idea of gene organization and expression and might contribute to understanding the molecular mechanisms involved in processes as disease diagnosis or drug discovery (Pharmacogenetics and Pharmacogenomics). The goal of the present review is to suggest a targeted use of DNA chip technology in the field of pharmacogenetics (with the example of antidepressants), suggesting the inclusion of only those genes, possibly candidates, through a step by step analysis of the pathways involved in the pharmacological action of antidepressants.
Export Options
About this article
Cite this article as:
Lorenzi Cristina, Tubazio Viviana, Serretti Alessandro and Ronchi De Diana, The Use of DNA Microarray in the Pharmacogenetics of Antidepressants: Guidelines for a Targeted Approach, Current Genomics 2004; 5 (6) . https://dx.doi.org/10.2174/1389202043348913
DOI https://dx.doi.org/10.2174/1389202043348913 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
New insights on Pediatric Tumors and Associated Cancer Predisposition Syndromes
Because of the broad spectrum of children cancer susceptibility, the diagnosis of cancer risk syndromes in children is rarely used in direct cancer treatment. The field of pediatric cancer genetics and genomics will only continue to expand as a result of increasing use of genetic testing tools. It's possible that ...read more
Related Journals
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome
Current Signal Transduction Therapy Advances in Targeting Insulin-like Growth Factor Signaling Pathway in Cancer Treatment
Current Pharmaceutical Design Lights and Shadows on Monoamine Oxidase Inhibition in Neuroprotective Pharmacological Therapies
Current Topics in Medicinal Chemistry Blockade of Insulin-Like Growth Factor Type-1 Receptor with Cixutumumab (IMC-A12): A Novel Approach to Treatment for Multiple Cancers
Current Drug Targets The Ligand Binding Region of the Sigma-1 Receptor: Studies Utilizing Photoaffinity Probes, Sphingosine and N-Alkylamines
Current Pharmaceutical Design Withdrawal Notice: Drug Repurposing for Prospective Anti-Cancer Agents Along with the Clinical Status of the Repurposed Drug
Anti-Cancer Agents in Medicinal Chemistry Prolonged Adrenal Insufficiency After the Discontinuation of Mitotane Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Conventional Chemotherapy and Emerging Targeted Therapy for Advanced Adrenocortical Carcinoma
Anti-Cancer Agents in Medicinal Chemistry A Novel Treatment Strategy for Sepsis and Septic Shock Based on the Interactions between Prostanoids, Nitric Oxide, and 20-Hydroxyeicosatetraenoic Acid
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Emerging Role of Melatonin Agonists in the Treatment of Major Depression: Focus on Agomelatine
CNS & Neurological Disorders - Drug Targets Non-coding RNAs and Hypertension–Unveiling Unexpected Mechanisms of Hypertension by the Dark Matter of the Genome
Current Hypertension Reviews Proinflammatory Cytokines and Sickness Behavior in Rheumatic Diseases
Current Pharmaceutical Design Impact of Early Life Stress on the Pathogenesis of Mental Disorders: Relation to Brain Oxidative Stress
Current Pharmaceutical Design Human Carbonyl Reductases
Current Drug Metabolism The Concept of Dysregulated Signal Transduction and Gene Expression in the Pathophysiology of Mood Disorders
Current Psychiatry Reviews Aldose Reductase Enzyme and its Implication to Major Health Problems of the 21st Century
Current Medicinal Chemistry Molecular Mechanisms Underlying Psychological Stress and Cancer
Current Pharmaceutical Design Neuroinflammation and Immunity: A New Pharmacological Target in Depression
CNS & Neurological Disorders - Drug Targets ES-MDA: Enhanced Similarity-based MiRNA-Disease Association
Current Protein & Peptide Science Systemic Redox Biomarkers in Neurodegenerative Diseases
Current Drug Metabolism